ABL is a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of virus for vaccine candidates, gene and cancer therapies. ABL's mission is to provide GMP viral vectors from early-stage to market, contributing to the success of their clients' immunotherapy innovations. ABL's CDMO services include bulk drug substance, fill/finish of drug products, process and assay development, and bioanalytical testing. ABL is a subsidiary of the Institut Mérieux. They operate from various locations in Europe and the US.